SEC Tracker
Get the app

Harmony Biosciences Holdings HRMY

Harmony Biosciences appoints new CEO

Item 5.02 Executive or director change

Form
8-K/A
Filed
Importance
Notable
  1. Dr. Jeffrey Dayno's separation agreement includes consulting services until 2028
  2. Peter Anastasiou's base salary is $725,000 starting 2026
  3. Anastasiou to receive $1.75M in stock options and $750K in restricted stock units (shares paid out over time)

Written from the 8-K/A on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Harmony Biosciences Holdings files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Travere Therapeutics TVTX public float $1.3B, Jun 30, 2025
  2. Ani Pharmaceuticals ANIP public float $1.3B, Jun 30, 2025
  3. Celldex Therapeutics CLDX public float $1.3B, Jun 30, 2025
  4. Adaptive Biotechnologies ADPT public float $1.4B, Jun 30, 2025
  5. Innoviva INVA public float $1.3B, Jun 30, 2025